AstraZeneca reaffirmed its target of reaching $80 billion in total revenue by 2030 during the 44th J.P. Morgan Healthcare Conference. The company first announced this goal in May 2024, which at the time surpassed analysts’ expectations.
Chief Financial Officer Aradhana Sarin addressed investors and analysts, stating that the $80 billion figure “was obviously a stretch target” when it was set, but AstraZeneca believed it was attainable. “A year and a half later, we do feel it is very much within reach,” Sarin said.
Sarin pointed out that consensus estimates have increased since the announcement. Forecasts for AstraZeneca’s revenue have risen from $67 billion in 2024 to about $76 billion by mid-2025, with current projections approaching the $80 billion mark. “I think people are getting more confident,” she said.
To achieve this growth, AstraZeneca plans to launch several high-value products soon. These include baxdrostat, camizestrant, and gefurulimab, all currently under regulatory review. Baxdrostat is being developed as an aldosterone synthase inhibitor to lower blood pressure in patients with resistant hypertension; its new drug application was accepted by the FDA last month. Camizestrant is an oral SERD aimed at breast cancer treatment, while gefurulimab targets complement C5 protein for generalized myasthenia gravis.
Sarin highlighted AstraZeneca’s oncology pipeline as central to its strategy. She emphasized antibody-drug conjugates (ADCs) as key contributors toward meeting the 2030 revenue goal. In particular, data for sonesitatug vedotin—which targets Claudin18.2 in second-line gastric cancer—are expected in the first half of this year. The company is also advancing puxitatug samrotecan for endometrial cancer and torvutatug samrotecan for ovarian cancer.
Overall, AstraZeneca has eight wholly owned clinical-stage ADCs that could address approximately 80% of patients within its targeted solid tumor areas.
The company’s cell therapy portfolio was also discussed at the conference. This includes AZD-0120 for multiple myeloma and surovatamig—a bispecific T cell engager—for blood cancers. Both treatments are part of AstraZeneca’s plan to reach its revenue target and each has a projected non-risk-adjusted peak revenue potential exceeding $5 billion.
